ABP-1119

N/A

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug NameABP-1119
Drug Alias Namemulti-TRK inhibitor (AB Pharma)ABP-1119
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitorsTyrosine-protein kinase BTK inhibitorsEpidermal growth factor receptor erbB1 inhibitors +[4] 
TargetsTyrosine-protein kinase BTKAnaplastic lymphoma kinaseReceptor protein-tyrosine kinase erbB-2 +[4] 
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesAb Pharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAb Pharma Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A